Table 1.

Changes in karyotype and TP53 mutation frequency of the present case.

Days after diagnosis, and aim of analysis		Leukemia phenotype	Karyotype [number of cells] and the frequency of cytogenetically abnormal cells (%)		TP53 mutation VAF (%)	MLL amplification (%)
0	Diagnosis (BM)	B-ALL	44, X, -X, add (1) (p13), add (2) (q21), -4, -5, -10, del(11)(q)?, -12, -14, -17, -18, +r1, +mar1, +mar2, +mar3, +mar4, +mar5 [3]/46, XX [4].	80 [16]/[20]	49.5	91.5
38	1st chemo evaluation (BM)	B-ALL	43, X, -X, add(1)(p13), add(2)(q21), -4, -5, -10, add(11)(q13), -12, -14, -17, -18, +mar1, +mar2, +mar3, +mar4, +mar5 [4]/44, idem, +r1 [3]/46, XX [11].	45 [9]/[20]	Not done	Not done
79	2nd chemo evaluation (BM)	B/T MPAL	43, X, -X, add(1)(p13), add(2)(q21), -4, -5, -10, add(11)(q13), -12, -14, -17, -18, +mar1, +mar2, +mar3, +mar4, +mar5 [2]/46, XX [5].	75 [15]/[20]	Note done	Not done
112	3rd chemo evaluation (BM)	B/T MPAL	44, X, -X, add(1)(p13), add(2)(q21), -4, -5, add(7)(q11.2), -10, add(11)(q13), -12, -14, -17, -18, +mar1, +mar2, +mar3, +mar4, +mar5, +mar6 [1]/87, idem x2, +5, +7, +7,-add(7) x2, -13, -mar3, -mar4, -mar5, -mar6 x2, +mar4 [1]/46, XX [6]	70 [14]/[20]	76.2	86.6
153	4th chemo evaluation (BM)	AML	45, X, -X, add(1)(p13), add(2)(q21), -4, -5, -8, -10, add(11)(q13), -12, -13, add(17)(p11.2), +mar1, +mar2, +mar3, +mar4, +mar5, +mar6 [1]/43, idem, -7, -add(17), +add(17)(p11.2), -mar6 [1]	100 [20]/[20]	94.1	64.7
198	5th chemo evaluation (PB)	AMML	43, X, -X, add(1)(p13), add(2)(q21), -4, -5, -8, -10, add(11)(q13), -12, -13, -17, +mar5 [1]/46, XX [2]	88.2 [15]/[17]	Not done	43.4
219	6thc chemo evaluation (PB)	AMML	43, X, -X, add(1)(p13), add(2)(q21), -4, -5, -7, -8, -10, add(11)(q13), -12, -13, -17, +6mar [1]	100 [10]/[10]	Not done	68.1
235	Died